SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-005561
Filing Date
2023-02-28
Accepted
2023-02-28 16:13:19
Documents
14
Period of Report
2023-02-28
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ngm-20230228.htm   iXBRL 8-K 38836
2 EX-99.1 ngm-20230228xexx99.htm EX-99.1 85917
6 ngmlogoprimarycopy.jpg GRAPHIC 26992
  Complete submission text file 0001628280-23-005561.txt   308798

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ngm-20230228.xsd EX-101.SCH 1881
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ngm-20230228_lab.xml EX-101.LAB 23832
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ngm-20230228_pre.xml EX-101.PRE 12495
8 EXTRACTED XBRL INSTANCE DOCUMENT ngm-20230228_htm.xml XML 11327
Mailing Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 333 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 650-243-5555
NGM BIOPHARMACEUTICALS INC (Filer) CIK: 0001426332 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38853 | Film No.: 23685436
SIC: 2834 Pharmaceutical Preparations